Medical Animation: PCSK9 LDL Cholesterol Regulation MOA
Created for Biopharmaceutical Client
Link copied!
Low density lipoproteins binding to LDL receptors (LDLR) on the hepatocyte. A therapeutic antibody binds to proprotein convertase subtilisin-like/Kexin type 9 (PCSK9) to prevent degradation of LDLR. © 2015. All Rights Reserved.
Low density lipoprotein (LDL) in blood stream surrounded by red blood cells (RBC). © 2015. All Rights Reserved.
Liver sinusoid containing erythrocytes (red blood cells, RBC) and low density lipoproteins (LDL) surrounded by hepatocytes. © 2015. All Rights Reserved.
The project
This medical animation explores the role of low density lipoprotein cholesterol (LDL-C) in atherosclerotic cardiovascular disease via regulation of LDL-C levels in the liver. By contrasting the LDL-C processing with and without PCSK9, we demonstrate how the latter is a therapeutic target for lowering LDL-C levels in hyperlipidemia. The medical animation goes on to explain the mechanism of action (MOA) of evolucumab, a PCSK9 inhibitor.
Created for
Biopharmaceutical client
